Meta Description: A clinical study examining the impact of LTS and Air-Q3 laryngeal mask airway devices on gastric insufflation using ultrasound during elective surgeries. Published on September 29, 2025.
An upcoming clinical trial led by Ankara City Hospital Bilkent will explore the comparative performance of two laryngeal mask airway (LMA) devices, LTS and Air-Q3, in minimizing gastric insufflation during elective surgeries. Using gastric ultrasonography as a monitoring tool, this study represents an important step in evaluating airway device safety and effectiveness in clinical settings.
Study Background
Airway management is critical in surgical settings, particularly to prevent complications such as gastric insufflation. Laryngeal mask airway devices provide an alternative to intubation, offering advantages in reduced trauma and ease of use. However, device selection can influence outcomes such as airway sealing efficiency and gastric insufflation rates.
The upcoming study, sponsored by Ankara City Hospital Bilkent, seeks to compare the LTS and Air-Q3 LMA devices regarding their effect on gastric insufflation. Ultrasonography, a non-invasive imaging method, will serve as the research metric to evaluate this effect, providing real-time and accurate insights into gastric content.
Methodology and Device Comparison
Clinical Trial Design
This trial will focus on elective surgical cases, where the controlled environment allows for precise measurement of outcomes. Participants will be randomized to receive either the LTS or Air-Q3 LMA device during airway management.
Ultrasonography as a Monitoring Tool
Gastric ultrasonography has emerged as a reliable technique for measuring gastric insufflation, and its deployment in this study ensures data accuracy. Information gleaned from ultrasonographic evaluation can offer enhanced decision-making for future device use.
Study Implications for Clinical Practice
Findings from this study will help healthcare providers make informed choices on LMA device selection, balancing effectiveness and safety. With gastric insufflation being a known risk factor for complications such as aspiration and compromised ventilation, identifying safer devices will improve surgical outcomes.
Manufacturers and regulatory bodies may also use this data to refine device designs and ensure compliance with international medical device standards, including MDR requirements for clinical safety and performance evaluation.
FAQ
1. What is gastric insufflation?
Gastric insufflation refers to the unintended inflation of the stomach with air during airway management. It can lead to complications such as aspiration risks.
2. Why is ultrasonography being used?
Ultrasonography provides a reliable, non-invasive method to evaluate gastric contents, allowing for real-time monitoring during the study.
3. Who is conducting the trial?
The trial is sponsored by Ankara City Hospital Bilkent and will focus on elective surgical cases for comparative assessment.
Conclusion
The evaluation of LTS and Air-Q3 LMA devices in preventing gastric insufflation is poised to deliver valuable data for clinicians and device manufacturers. With ultrasonography anchoring the trial as a precise measurement tool, results could refine airway management strategies in elective surgeries and beyond.
Disclaimer
This article is informational and intended for professionals. It does not constitute legal or clinical advice. Always consult with regulatory or clinical resources for specific guidance.
Announcement Link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07196137?term=medical+device